Clinical Trial Update: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating RXC007 for idiopathic pulmonary fibrosis, focusing on safety, pharmacokinetics, pharmacodynamics, and clinical activity…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosis
• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• RXC007

Snippet

Sponsor: Redx Pharma Ltd | Conditions: IPF, Fibrosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING